These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38844408)

  • 21. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
    Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.
    Howlett S; Carter TJ; Shaw HM; Nathan PD
    Ther Adv Med Oncol; 2023; 15():17588359231160140. PubMed ID: 36970111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
    Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
    Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.
    Maio M; Danielli R; Chiarion-Sileni V; Pigozzo J; Parmiani G; Ridolfi R; De Rosa F; Del Vecchio M; Di Guardo L; Queirolo P; Picasso V; Marchetti P; De Galitiis F; Mandalà M; Guida M; Simeone E; Ascierto PA
    Ann Oncol; 2013 Nov; 24(11):2911-5. PubMed ID: 24067719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events.
    Koch EAT; Petzold A; Dippel E; Erdmann M; Gesierich A; Gutzmer R; Hassel JC; Haferkamp S; Kähler KC; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schell B; Terheyden P; Thoms KM; Ugurel S; Ulrich J; Utikal J; Weichenthal M; Ziller F; Berking C; Heppt MV
    Front Immunol; 2024; 15():1395225. PubMed ID: 38915414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
    Sander MS; Stukalin I; Vallerand IA; Goutam S; Ewanchuk BW; Meyers DE; Pabani A; Morris DG; Heng DYC; Cheng T
    Cancer Med; 2021 Apr; 10(8):2618-2626. PubMed ID: 33724676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
    Seremet T; Jansen Y; Planken S; Njimi H; Delaunoy M; El Housni H; Awada G; Schwarze JK; Keyaerts M; Everaert H; Lienard D; Del Marmol V; Heimann P; Neyns B
    J Transl Med; 2019 Sep; 17(1):303. PubMed ID: 31488153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis.
    Dian Y; Liu Y; Zeng F; Sun Y; Deng G
    Hum Vaccin Immunother; 2024 Dec; 20(1):2374647. PubMed ID: 39004419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor lysis syndrome induced by tebentafusp.
    Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L
    Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
    Reiter S; Schroeder C; Broche J; Sinnberg T; Bonzheim I; Süsskind D; Flatz L; Forschner A
    Front Oncol; 2023; 13():1167791. PubMed ID: 37207136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
    Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
    JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
    Bhatia S; Moon J; Margolin KA; Weber JS; Lao CD; Othus M; Aparicio AM; Ribas A; Sondak VK
    PLoS One; 2012; 7(11):e48787. PubMed ID: 23226204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
    Zager JS; Orloff M; Ferrucci PF; Choi J; Eschelman DJ; Glazer ES; Ejaz A; Howard JH; Richtig E; Ochsenreither S; Reddy SA; Lowe MC; Beasley GM; Gesierich A; Bender A; Gschnell M; Dummer R; Rivoire M; Arance A; Fenwick SW; Sacco JJ; Haferkamp S; Weishaupt C; John J; Wheater M; Ottensmeier CH
    Ann Surg Oncol; 2024 Aug; 31(8):5340-5351. PubMed ID: 38704501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
    Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph R; Weber JS; Dronca R; Mitchell TC; Patnaik A; Zarour HM; Joshua AM; Zhao Q; Jensen E; Ahsan S; Ibrahim N; Ribas A
    Ann Oncol; 2019 Apr; 30(4):582-588. PubMed ID: 30715153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
    Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
    Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tebentafusp in first-line melanoma trials: An outperforming outlier.
    Olivier T; Prasad V
    Transl Oncol; 2022 Jun; 20():101408. PubMed ID: 35364557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?
    Bender C; Enk A; Gutzmer R; Hassel JC
    Cancer Med; 2017 Jul; 6(7):1581-1586. PubMed ID: 28639409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
    Schinzari G; Rossi E; Cassano A; Dadduzio V; Quirino M; Pagliara M; Blasi MA; Barone C
    Melanoma Res; 2017 Dec; 27(6):591-595. PubMed ID: 29076951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
    Alexander M; Mellor JD; McArthur G; Kee D
    Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.